BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-04
190 industry Phase 2/3 trial readout(s) and 55 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-04 est. | P2/P3 | Johnpro Biotech, Inc. | NCT03008148 Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | Glioblastoma | unknown | 288 |
| 2025-04 est. | P1/P2 | Oblato, Inc. | NCT03649464 Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | Glioblastoma; Astrocytoma; Oligodendroglioma | withdrawn | |
| 2025-04 est. | P3 | Angiodynamics, Inc. ANGO | NCT03899636 A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer | Stage III Pancreatic Cancer | active not recruiting | 528 |
| 2025-04 est. | P3 | Mallinckrodt | NCT04128462 MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function | Hepatic Encephalopathy | withdrawn | |
| 2025-04 est. | P3 | EMS | NCT04603508 Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia | Type 2 Diabetes Mellitus; Dyslipidemia | unknown | 240 |
| 2025-04 est. | P1/P2 | Nelum Corp | NCT04827953 Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | active not recruiting | 28 |
| 2025-04 est. | P1/P2 | Suzhou Kintor Pharmaceutical Inc, | NCT04984668 A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | Solid Tumor | unknown | 216 |
| 2025-04 est. | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05552937 Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | DLBCL | recruiting | 50 |
| 2025-04 est. | P1/P2 | Shandong Qilu Stem Cells Engineering Co., Ltd. | NCT05794425 Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders | Bone Marrow Failure Disorders | unknown | 100 |
| 2025-04 est. | P3 | Livzon Pharmaceutical Group Inc. | NCT06110676 A Study to Evaluate the Efficacy and Safety of LZM012 | Psoriasis | unknown | 918 |
| 2025-04 est. | P3 | Natural Wellness Egypt | NCT06141200 NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial | Essential Hypertension | unknown | 286 |
| 2025-04 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06261359 A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma (PDAC) | unknown | 120 |
| 2025-04 est. | P1/P2 | Eyestem Research Pvt. Ltd. | NCT06394232 Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. | Retinal Disease; Macular Degeneration; Age-Related Macular Degeneration; Geographic Atrophy; Eye Dis | recruiting | 54 |
| 2025-04 est. | P2 | DermBiont, Inc. | NCT06454747 Randomized Study Using SM-030 Gel for Adults With Melasma | Melasma | recruiting | 138 |
| 2025-04 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06731829 A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions | For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions | not yet recruiting | 78 |
| 2025-04-01 | P3 | Sanofi SNY | NCT03560466 Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) | Asthma | completed | 378 |
| 2025-04-01 | P1/P2 | Genmab GMAB | NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Solid Tumors | terminated | 429 |
| 2025-04-01 | P1/P2 | Incyte Corporation INCY | NCT04455841 INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders | Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis | completed | 84 |
| 2025-04-01 | P1/P2 | Servier Bio-Innovation LLC | NCT05159388 A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors | Solid Tumor | terminated | 46 |
| 2025-04-01 est. | P2 | Suzhou Kintor Pharmaceutical Inc, | NCT05178043 GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma; HCC | unknown | 5 |
| 2025-04-01 est. | P1/P2 | Beijing Immunochina Medical Science & Technology Co., Ltd. | NCT05309213 Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | Leukemia | unknown | 58 |
| 2025-04-01 est. | P2/P3 | NuvOx LLC NUOX | NCT05389748 NanO2 for Large Vessel Occlusion Stroke | Ischemic Stroke | unknown | 300 |
| 2025-04-01 | P1/P2 | Daiichi Sankyo | NCT05638802 A Study of DS-7011a in Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | completed | 26 |
| 2025-04-01 est. | P3 | CanSino Biologics Inc. | NCT05951725 A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) | Diphtheria, Tetanus and Acellular Pertussis | active not recruiting | 2520 |
| 2025-04-01 est. | P1/P2 | Guangzhou Gloria Biosciences Co., Ltd. | NCT05978401 Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | Advanced Non-Small Cell Lung Cancer | unknown | 152 |
| 2025-04-01 | P2 | Eli Lilly and Company LLY | NCT06176768 A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | completed | 33 |
| 2025-04-01 est. | P2 | Fujian Akeylink Biotechnology Co., Ltd. | NCT06263959 A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepati | Chronic Hepatitis B | recruiting | 45 |
| 2025-04-01 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT06383702 A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | unknown | 358 |
| 2025-04-01 | P2 | Medex d.o.o. | NCT06573814 The Effects of Bio Gelee Royale Forte on Immune Health in Healthy Adults | Upper Respiratory Tract Infection; URTI | completed | 100 |
| 2025-04-02 | P3 | Prothena Biosciences Ltd. PRTA | NCT04973137 A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis | Light Chain (AL) Amyloidosis | terminated | 208 |
| 2025-04-02 | P1/P2 | GlaxoSmithKline | NCT05089630 A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults | Cytomegalovirus Infections | completed | 333 |
| 2025-04-02 | P3 | Lyra Therapeutics | NCT05295459 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) | Chronic Sinusitis; Chronic Rhinosinusitis (Diagnosis) | completed | 182 |
| 2025-04-02 | P3 | Marinus Pharmaceuticals | NCT05604170 Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy | Tuberous Sclerosis Complex | terminated | 117 |
| 2025-04-02 | P3 | Novo Nordisk A/S NVO | NCT06041217 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range | Overweight; Obesity | completed | 242 |
| 2025-04-02 | P3 | Tasly Pharmaceutical Group Co., Ltd | NCT06068478 A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis | Gouty Arthritis | completed | 472 |
| 2025-04-02 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06561841 A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | completed | 47 |
| 2025-04-03 | P2 | Takeda TAK | NCT03196427 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Ulcerative Colitis; Crohn's Disease | completed | 59 |
| 2025-04-03 | P3 | AstraZeneca AZN | NCT03528694 Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer | Non-muscle-invasive Bladder Cancer | active not recruiting | 1018 |
| 2025-04-03 | P3 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) | Pulmonary Arterial Hypertension | terminated | 321 |
| 2025-04-03 | P2 | GemVax & Kael | NCT05189210 GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) | Mild to Moderate Alzheimer's Disease | completed | 199 |
| 2025-04-03 | P1/P2 | BerGenBio ASA | NCT05469178 A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in | Carcinoma, Non-Small-Cell Lung | terminated | 26 |
| 2025-04-03 | P1/P2 | Alnylam Pharmaceuticals ALNY | NCT05761301 A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | Type 2 Diabetes Mellitus (T2DM) | terminated | 49 |
| 2025-04-03 | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT05779163 A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors | Advanced Malignant Tumors | completed | 26 |
| 2025-04-03 | P3 | Eli Lilly and Company LLY | NCT05971940 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Type 2 Diabetes | completed | 559 |
| 2025-04-03 | P2 | Perfuse Therapeutics, Inc. | NCT06003751 A Study of PER-001 in Participants With Diabetic Retinopathy | Diabetic Retinopathy | completed | 27 |
| 2025-04-03 | P1/P2 | Novakand Pharma AB | NCT06087289 A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Perit | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer | completed | 18 |
| 2025-04-03 | P3 | Opus Genetics, Inc IRD | NCT06542497 Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia | Presbyopia | completed | 569 |
| 2025-04-03 | P2 | Inventprise Inc. | NCT06790290 Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants | Pneumococcal Disease, Invasive | active not recruiting | 421 |
| 2025-04-04 | P2 | CARGO Therapeutics | NCT05972720 A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma | Cancer; Relapsed/Refractory Large B-cell Lymphoma (LBCL) | terminated | 101 |
| 2025-04-04 | P2 | Pliant Therapeutics, Inc. PLRX | NCT06097260 Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | terminated | 320 |
| 2025-04-04 | P2 | Zomagen Biosciences Ltd. | NCT06556173 Phase 2a Study of VTX3232 in Parkinson's Disease | Idiopathic Parkinson Disease | completed | 11 |
| 2025-04-04 | P3 | BioNet-Asia Co., Ltd. | NCT06798831 Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults | Pertussis Vaccine | active not recruiting | 2399 |
| 2025-04-07 | P2/P3 | Sun Pharmaceutical Industries Limited | NCT03997786 A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis | Moderate-to-severe Chronic Plaque Psoriasis | active not recruiting | 135 |
| 2025-04-07 | P3 | AstraZeneca AZN | NCT04931563 Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE) | Active Systemic Lupus Erythematosus | completed | 277 |
| 2025-04-07 | P3 | Merck Sharp & Dohme LLC MRK | NCT05952869 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) | Hypercholesterolemia; Familial Hypercholesterolemia | completed | 303 |
| 2025-04-07 | P3 | Addpharma Inc. | NCT06291207 A Study to Evaluate the Efficacy and Safety of AD-224 | Hypertension,Essential | completed | 254 |
| 2025-04-07 | P3 | Shanghai Ark Biopharmaceutical Co., Ltd. | NCT06775405 A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants | Respiratory Synctial Virus Infections | completed | 180 |
| 2025-04-08 | P3 | AbbVie ABBV | NCT02632175 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis | Ulcerative Colitis | completed | 59 |
| 2025-04-08 | P3 | Alexion Pharmaceuticals, Inc. | NCT04512235 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | AL Amyloidosis | active not recruiting | 281 |
| 2025-04-08 | P3 | Anterogen Co., Ltd. | NCT04612465 Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula | Crohn's Fistula | active not recruiting | 46 |
| 2025-04-08 | P3 | Janssen Research & Development, LLC | NCT06514742 A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Re | Depressive Disorder, Major; Anhedonia | terminated | 101 |
| 2025-04-08 | P2 | Sanofi SNY | NCT06949358 A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the | Acid Sphingomyelinase Deficiency | completed | 3 |
| 2025-04-09 | P1/P2 | Otsuka Pharmaceutical Co., Ltd. | NCT04649073 Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma (MM) | terminated | 11 |
| 2025-04-09 | P3 | Lipogems International spa | NCT05660772 Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis | Knee Osteoarthritis; Osteo Arthritis Knee | completed | 173 |
| 2025-04-09 | P2 | Recognify Life Sciences | NCT05686239 A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) | Cognitive Impairment Associated With Schizophrenia (CIAS); Cognitive Impairment; Schizophrenia | completed | 242 |
| 2025-04-09 | P2 | Merck Sharp & Dohme LLC MRK | NCT06099782 A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK | Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma | active not recruiting | 147 |
| 2025-04-09 | P2 | Neumora Therapeutics, Inc. NMRA | NCT06429722 To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder. | Major Depressive Episode Associated With Bipolar II Disorder | completed | 18 |
| 2025-04-09 | P3 | Janssen Research & Development, LLC | NCT06635135 A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of In | Depressive Disorder, Major; Anhedonia | terminated | 47 |
| 2025-04-10 | P1/P2 | Sangamo Therapeutics SGMOQ | NCT04046224 Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) | Fabry Disease | completed | 36 |
| 2025-04-10 | P3 | Astellas Pharma Global Development, Inc. | NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy | Geographic Atrophy; Age-Related Macular Degeneration | completed | 278 |
| 2025-04-10 est. | P1/P2 | Biotheus Inc. | NCT05839106 Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors | Advanced Tumor | unknown | 200 |
| 2025-04-10 | P2 | Bristol-Myers Squibb BMY | NCT06101134 A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Comb | Melanoma | active not recruiting | 100 |
| 2025-04-10 | P2 | Novo Nordisk A/S NVO | NCT06326060 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | Obesity | completed | 354 |
| 2025-04-10 | P2 | Sunhawk Vision Biotech, Inc. | NCT06381986 Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients | Corneal Erosion | completed | 116 |
| 2025-04-11 | P3 | Merck Sharp & Dohme LLC MRK | NCT04029480 Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) | Type 2 Diabetes Mellitus | completed | 166 |
| 2025-04-11 | P3 | Nicox Ophthalmics, Inc. | NCT04630808 MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension | Open Angle Glaucoma; Ocular Hypertension | completed | 696 |
| 2025-04-11 | P3 | Sanofi SNY | NCT04701983 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | completed | 1127 |
| 2025-04-11 | P3 | Novartis Pharmaceuticals NVS | NCT04930094 Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (G | Giant Cell Arteritis (GCA) | completed | 354 |
| 2025-04-11 | P3 | Amgen AMGN | NCT06224192 A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis | Atopic Dermatitis | completed | 151 |
| 2025-04-11 | P2/P3 | Boehringer Ingelheim | NCT06241573 A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Stu | Hidradenitis Suppurativa (HS) | terminated | 39 |
| 2025-04-11 | P2 | Veru Inc. VERU | NCT06282458 Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt | Muscle Loss; Obesity | completed | 168 |
| 2025-04-12 | P3 | ModernaTX, Inc. | NCT05815498 A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 | COVID-19 | completed | 13553 |
| 2025-04-12 | P3 | Summit Therapeutics SMMT | NCT06396065 Phase III Study of AK112 for NSCLC Patients | Non-Squamous Non-small Cell Lung Cancer | active not recruiting | 420 |
| 2025-04-14 | P2 | Celgene | NCT02494258 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders | Hematologic Neoplasm; Neoplasms; Hematologic Malignancies | completed | 5 |
| 2025-04-14 | P3 | Instituto Grifols, S.A. | NCT03702920 Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% | Acute-On-Chronic Liver Failure | terminated | 274 |
| 2025-04-14 | P3 | PolyPid Ltd. PYPD | NCT04411199 D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II) | Surgical Site Infection; Colon Surgery; Abdominal Surgery; Post-Op Infection | completed | 975 |
| 2025-04-14 | P2 | Orano Med LLC | NCT05153772 Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients | Neuroendocrine Tumors | active not recruiting | 69 |
| 2025-04-14 | P3 | Novo Nordisk A/S NVO | NCT05813912 A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type | Diabetes Mellitus, Type 2 | completed | 148 |
| 2025-04-14 | P3 | Alexion Pharmaceuticals, Inc. | NCT05886244 Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China | Paroxysmal Nocturnal Hemoglobinuria | completed | 25 |
| 2025-04-14 | P3 | Janssen Research & Development, LLC | NCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis | Moderate Plaque Psoriasis | completed | 338 |
| 2025-04-14 | P2 | Alto Neuroscience ANRO | NCT06391593 PD, PK, and Safety of ALTO-203 in Patients With MDD | Major Depressive Disorder; Anhedonia | completed | 69 |
| 2025-04-15 est. | P2 | Can-Fite BioPharma CANF | NCT04697810 Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | NASH - Nonalcoholic Steatohepatitis | unknown | 114 |
| 2025-04-15 | P3 | PTC Therapeutics PTC | NCT05218655 A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease | Inherited Mitochondrial Disease | completed | 101 |
| 2025-04-15 | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06099652 Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease | Pulmonary Disease, Chronic Obstructive | completed | 142 |
| 2025-04-15 | P3 | Colgate Palmolive CL | NCT06732466 Evaluation of the Effect of a Toothpaste Containing 0.3% Chlorhexidine in Subjects With Established Dental Plaque and Gingivitis | Gingivitis; Gingivitis and Periodontal Diseases; Gingival Disease; Dental Plaque | completed | 80 |
| 2025-04-15 est. | P3 | Livzon Pharmaceutical Group Inc. | NCT06850480 A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis | Reflux Esophagitis (RE) | recruiting | 356 |
| 2025-04-15 | P3 | Laboratorios Richmond S.A.C.I.F. | NCT07448506 Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension | High Blood Pressure (& [Essential Hypertension]) | completed | 50 |
| 2025-04-16 | P3 | Novartis Pharmaceuticals NVS | NCT04717635 Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD | Adult Onset Still's Disease | completed | 14 |
| 2025-04-16 | P1/P2 | Arrowhead Pharmaceuticals ARWR | NCT05276570 Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease | Asthma | completed | 127 |
| 2025-04-16 | P2 | Sensorion | NCT05628233 SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease | Hearing Loss Ototoxic | completed | 48 |
| 2025-04-16 | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT06006689 Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) | Diabetic Kidney Disease | completed | 228 |
| 2025-04-16 | P3 | BioMarin Pharmaceutical BMRN | NCT06224907 Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A | Hemophilia A | active not recruiting | 6 |
| 2025-04-16 | P1/P2 | Takeda TAK | NCT06390995 A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | Ovarian Cancer; Solid Tumors | active not recruiting | 28 |
| 2025-04-16 | P2 | Gilead Sciences GILD | NCT06784973 Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection | RSV Infection | terminated | 4 |
| 2025-04-17 | P1/P2 | GlaxoSmithKline | NCT04126200 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma ( | Multiple Myeloma | active not recruiting | 208 |
| 2025-04-17 | P2 | Cloudbreak Therapeutics, LLC | NCT04884256 Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula | Pinguecula | completed | 88 |
| 2025-04-17 | P2 | Longbio Pharma | NCT06228560 Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment | Chronic Spontaneous Urticaria | completed | 202 |
| 2025-04-17 | P3 | Opus Genetics, Inc IRD | NCT06349759 Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances | Mesopic Vision; Night Vision Loss | completed | 200 |
| 2025-04-17 | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06726850 Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women. | Vasomotor Syndrome | completed | 129 |
| 2025-04-17 | P1/P2 | GlaxoSmithKline | NCT07084896 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | Multiple Myeloma | active not recruiting | 106 |
| 2025-04-17 | P1/P2 | GlaxoSmithKline | NCT07150091 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | Multiple Myeloma | active not recruiting | 20 |
| 2025-04-17 | P1/P2 | GlaxoSmithKline | NCT07150104 Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | Multiple Myeloma | active not recruiting | 14 |
| 2025-04-17 | P1/P2 | GlaxoSmithKline | NCT07217119 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM | Multiple Myeloma | active not recruiting | 25 |
| 2025-04-17 | P1/P2 | GlaxoSmithKline | NCT07217184 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | Multiple Myeloma | active not recruiting | 30 |
| 2025-04-18 | P3 | Regeneron Pharmaceuticals REGN | NCT03088540 Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Carcinoma,Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsm | completed | 712 |
| 2025-04-18 | P3 | Lynk Pharmaceuticals Co., Ltd | NCT06277245 A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. | Atopic Dermatitis | completed | 356 |
| 2025-04-18 | P2 | AstraZeneca AZN | NCT06692764 A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure | Atherosclerotic Cardiovascular Disease | completed | 202 |
| 2025-04-18 | P2 | TJ Biopharma Co., Ltd. | NCT07034209 A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immun | Hemophagocytic Lymphohistiocytoses | completed | 18 |
| 2025-04-19 est. | P2 | Gwo Xi Stem Cell Applied Technology Co., Ltd. | NCT04088058 A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis | Liver Cirrhosis | unknown | 20 |
| 2025-04-20 | P1/P2 | Perfuse Therapeutics, Inc. | NCT05822245 A Study of PER-001 in Participants With Open-Angle Glaucoma | Open-angle Glaucoma | completed | 33 |
| 2025-04-21 | P3 | Sanofi SNY | NCT04751487 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | completed | 1234 |
| 2025-04-21 | P2/P3 | Mirati Therapeutics Inc. | NCT04887870 Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | Advanced or Metastatic Solid Malignancies | completed | 49 |
| 2025-04-21 | P2 | Tonix Pharmaceuticals, Inc. TNXP | NCT06045793 Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) | Cocaine Use; Cocaine Intoxication; Cocaine Toxicity; Cocaine Abuse; Cocaine Adverse Reaction | terminated | 3 |
| 2025-04-22 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT03238326 Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia | Schizophrenia | completed | 295 |
| 2025-04-22 | P3 | Equillium EQ | NCT05263999 A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) | Graft Versus Host Disease; GVHD; Acute-graft-versus-host Disease; Acute GVHD; aGVHD | terminated | 158 |
| 2025-04-22 | P3 | Bio-Thera Solutions | NCT05439629 Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration | Neovascular (Wet) Age-related Macular Degeneration | completed | 488 |
| 2025-04-22 est. | P2 | AbbVie ABBV | NCT05606757 A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement o | Ventral Hernia; Abdominal Hernia | withdrawn | |
| 2025-04-22 | P1/P2 | GeneCradle Inc | NCT05901987 Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients | SMA II | completed | 29 |
| 2025-04-22 | P2 | Senhwa Biosciences, Inc. | NCT06202521 CX-4945 in Viral Community Acquired Pneumonia | Community-acquired Pneumonia; SARS-CoV-2 -Associated Pneumonia; Influenza With Pneumonia | terminated | 45 |
| 2025-04-22 | P2 | Lassen Therapeutics Inc. | NCT06226545 A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease | Thyroid Eye Disease; Graves Ophthalmopathy; Graves Orbitopathy; Thyroid Associated Ophthalmopathy; E | completed | 41 |
| 2025-04-22 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07295418 A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia | Hyperlipidemias | completed | 618 |
| 2025-04-23 | P2 | Debiopharm International SA | NCT03723551 Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus | Bone or Joint Infection | terminated | 67 |
| 2025-04-23 | P2/P3 | Pfizer PFE | NCT04173273 A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | terminated | 379 |
| 2025-04-23 | P3 | Mirum Pharmaceuticals, Inc. MIRM | NCT04185363 An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) | Progressive Familial Intrahepatic Cholestasis (PFIC) | completed | 84 |
| 2025-04-23 | P3 | Rejoni Inc. | NCT05394662 Safety and Effectiveness of Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine Adhesions | Intrauterine Adhesion | completed | 150 |
| 2025-04-23 | P1/P2 | Clarity Pharmaceuticals Ltd | NCT05633160 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Ca | Prostatic Neoplasms; Castration-Resistant | terminated | 4 |
| 2025-04-23 | P2 | Rion Inc. | NCT06319287 Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU) | Diabetic Foot Ulcer | completed | 59 |
| 2025-04-23 | P2/P3 | Lallemand Pharma AG | NCT06582589 HEALSea Nasal Spray for Prevention of Infections in Children | Healthy Subjects | completed | 139 |
| 2025-04-23 | P3 | Regeneron Pharmaceuticals REGN | NCT06602739 A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy | Allergic Conjunctivitis | completed | 54 |
| 2025-04-24 | P3 | Camurus AB | NCT04125836 A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | Acromegaly | completed | 135 |
| 2025-04-24 | P2 | Trevi Therapeutics TRVI | NCT05964335 Cough Reduction in IPF With Nalbuphine ER | Idiopathic Pulmonary Fibrosis | completed | 165 |
| 2025-04-24 | P3 | GlaxoSmithKline | NCT06551181 A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV | Respiratory Syncytial Virus Infections | completed | 2620 |
| 2025-04-24 | P3 | Colgate Palmolive CL | NCT06732518 Evaluation of the Anti-cavity Efficacy of Three Dentifrices Using an Intra-oral Enamel Demineralization - Remineralization In-Situ Model | Enamel Lesions; Demineralization, Tooth; Remineralization; Dental Cavity | completed | 36 |
| 2025-04-24 | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06751121 Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori | Helicobacter Pylori Infection; Helicobacter Pylori Infected Patients; Helicobacter Pylori Infected S | completed | 461 |
| 2025-04-25 | P2 | Sparrow Pharmaceuticals | NCT05436652 A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) | Polymyalgia Rheumatica | completed | 66 |
| 2025-04-25 | P3 | Janssen Research & Development, LLC | NCT05518149 A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) | Depressive Disorder, Major | terminated | 871 |
| 2025-04-25 | P1/P2 | ModernaTX, Inc. | NCT06033261 A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herp | Genital Herpes | completed | 303 |
| 2025-04-25 | P3 | Viridian Therapeutics, Inc. VRDN | NCT06179875 An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 | Thyroid Eye Disease | completed | 139 |
| 2025-04-25 | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06423794 BHV-7000 Open-Label Extension Bipolar Mania Study | Bipolar Disorder | terminated | 94 |
| 2025-04-26 | P2 | Novartis Pharmaceuticals NVS | NCT04797000 Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence | Myelodysplastic Syndromes | active not recruiting | 36 |
| 2025-04-27 | P2 | Takeda TAK | NCT05673785 A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Posit | Lymphoma | active not recruiting | 52 |
| 2025-04-27 | P1/P2 | Beijing Inno Medicine Co., Ltd. | NCT06048588 YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis | Atherosclerotic Cardiovascular Disease | completed | 144 |
| 2025-04-28 | P2 | Galderma R&D | NCT04921345 Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis | Moderate-to-Severe Atopic Dermatitis | completed | 109 |
| 2025-04-28 | P3 | Merck Sharp & Dohme LLC MRK | NCT04938830 Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) | RSV Infection | completed | 1003 |
| 2025-04-28 | P3 | AbbVie ABBV | NCT05748483 Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine | Migraine | completed | 545 |
| 2025-04-28 | P1/P2 | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | NCT06719310 Phase Ib/IIa Clinical Study of ACC017 Tablets | Infection, Human Immunodeficiency Virus | completed | 36 |
| 2025-04-29 | P3 | Pfizer PFE | NCT03938792 Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B | Hemophilia A; Hemophilia B | completed | 188 |
| 2025-04-29 | P3 | Novo Nordisk A/S NVO | NCT04596631 A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Diabetes Mellitus, Type 2 | completed | 132 |
| 2025-04-29 | P3 | Biohaven Pharmaceuticals, Inc. BHVN | NCT04693351 A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder | Obsessive-Compulsive Disorder | completed | 589 |
| 2025-04-29 | P2 | Suzhou Ribo Life Science Co. Ltd. | NCT05961098 A Study of RBD1016 in CHB Participants | Chronic Hepatitis b | completed | 48 |
| 2025-04-29 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06049810 IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment | Psoriasis | completed | 566 |
| 2025-04-30 | P2 | Celgene | NCT01946477 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or | Multiple Myeloma | completed | 186 |
| 2025-04-30 | P2 | Merck Sharp & Dohme LLC MRK | NCT04165096 KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell | Carcinoma, Non-Small-Cell Lung | completed | 128 |
| 2025-04-30 | P2 | DAS-MG, Inc | NCT04226170 Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis | Myasthenia Gravis | terminated | 2 |
| 2025-04-30 | P1/P2 | TJ Biopharma Co., Ltd. | NCT04322006 A Phase I/II Study of TJ004309 for Advanced Solid Tumor | Advanced Solid Tumor | completed | 225 |
| 2025-04-30 est. | P2 | Zensun Sci. & Tech. Co., Ltd. | NCT04859621 Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections | Recurrent Urinary Tract Infection | unknown | 150 |
| 2025-04-30 est. | P1/P2 | Cyclacel Pharmaceuticals, Inc. | NCT04983810 A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | Solid Tumor, Adult; Lymphoma | unknown | 330 |
| 2025-04-30 est. | P3 | Sandoz | NCT05070650 Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold | Common Cold | withdrawn | |
| 2025-04-30 | P2/P3 | Zydus Therapeutics Inc. | NCT05133336 Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis | Primary Biliary Cholangitis | completed | 196 |
| 2025-04-30 | P1/P2 | Allist Pharmaceuticals, Inc. | NCT05194995 JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | Advanced Colorectal Cancer; Small Intestinal Cancer; Appendiceal Cancer | active not recruiting | 48 |
| 2025-04-30 est. | P2 | IO Biotech | NCT05280314 Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | Melanoma; Squamous Cell Carcinoma of Head and Neck | recruiting | 60 |
| 2025-04-30 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT05367778 Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors | Advanced Solid Tumor | unknown | 176 |
| 2025-04-30 | P2 | Akeso | NCT05432492 A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | completed | 40 |
| 2025-04-30 | P2 | Kezar Life Sciences, Inc. | NCT05569759 A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) | Autoimmune Hepatitis | completed | 24 |
| 2025-04-30 | P1/P2 | NextCure, Inc. NXTC | NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors; Microsatellite Instability Low; Microsatellite Instability High | terminated | 97 |
| 2025-04-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05636215 A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors | recruiting | 368 |
| 2025-04-30 | P1/P2 | Genfleet Therapeutics (Shanghai) Inc. | NCT05756153 A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation | Advance Non-small Cell Lung Cancer | completed | 47 |
| 2025-04-30 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05765032 Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors | Advanced Solid Tumor | unknown | 220 |
| 2025-04-30 est. | P2 | Biotheus Inc. | NCT05879068 A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | SCLC | active not recruiting | 99 |
| 2025-04-30 est. | P1/P2 | Shanghai Kanda Biotechnology Co., Ltd. | NCT05906524 KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors | Advanced HCC; Other Solid Tumors | unknown | 85 |
| 2025-04-30 | P3 | Almirall, S.A. | NCT06135415 A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis | Keratosis, Actinic | completed | 280 |
| 2025-04-30 | P1/P2 | Immuneering Corporation IMRX | NCT06208124 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Advanced Solid Tumor (Phase 1); Pancreas Adenocarcinoma; Non-small Cell Lung Cancer; Malignant Melan | completed | 30 |
| 2025-04-30 est. | P1/P2 | BriaCell Therapeutics Corporation BCTX | NCT06471673 A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | Breast Cancer; Breast Tumor; Cancer of Breast; Cancer of the Breast; Malignant Tumor of Breast; Tumo | unknown | 18 |
| 2025-04-30 est. | P2 | Shanghai Ming Ju Biotechnology Co., Ltd. | NCT06479356 CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | Non-Hodgkin Lymphoma; Large B-cell Lymphoma | recruiting | 12 |
| 2025-04-30 | P3 | AO GENERIUM | NCT06488664 An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 422 |
| 2025-04-30 | P2 | Huabo Biopharm Co., Ltd. | NCT06592274 A Phase 2 Study of HB0017 in Psoriasis Patients | Psoriasis (PsO) | completed | 206 |
| 2025-04-30 | P2 | Okyo Pharma Ltd OKYO | NCT06637527 The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain | Neuropathic Pain | terminated | 18 |
| 2025-04-30 est. | P1/P2 | Zhuhai Yufan Biotechnologies Co., Ltd | NCT06727630 A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma | Melanoma | unknown | 40 |
| 2025-04-30 | P2 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | NCT06760182 Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | completed | 169 |
| 2025-04-30 | P1/P2 | noiVita Srls | NCT07110480 Combination of Equisetum Arvense and Palmitoylethanolamide (PEA) for the Management of Patients With Chronic Pain in a Before-after Study | Chronic Pain; Chronic Pain (Back / Neck); Pain (Visceral, Somatic, or Neuropathic); Pain Management | completed | 50 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.